The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer

He, Min; Zhang, Jia Xin; Jiang, Yi; Chen, Ying Le; Yang, Hong Yul; Tang, Li; Di, Gen-Hong

doi:10.18632/oncotarget.17413

Cited by 19 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It revealed that the LNR was an independent predictor of OS in high-risk patients. Considering the heterogeneity of TNBC, the LNR exhibits potential as an additional prognostic factor for TNBC patients with positive lymph node involvement [11]. In our study, we have also found that higher clinical N-stage is associated with increased ORs of distant metastasis.…”

Section: Discussionsupporting

confidence: 73%

Risk factors for distant metastasis of patients with primary triple-negative breast cancer

Yao

Chu

et al. 2019

Bioscience Reports

View full text Add to dashboard Cite

Objective: Triple-negative breast cancer (TNBC) involves higher rates of recurrence and distant metastasis. The present study sought to characterize the risk factors for distant metastasis of TNBC. Methods: The Surveillance, Epidemiology, and End Results (SEER) database was exploited to enroll patients diagnosed with TNBC from 2010 to 2015. The eligible patients were dichotomized into locoregional and distant metastasis at the time of diagnosis. Patients’ demographics and tumor features, and treatment were evaluated to identify the risk factors for distant metastasis of primary TNBC. The categorical variables were examined by chi-square tests. Univariate and multivariate logistic regression analyses were used to determine the risk factors for distant metastasis. Breast cancer-specific survival (BCSS) and overall survival (OS) were estimated by Kaplan–Meier plots with log-rank tests. Results: We collected 26863 patients with primary TNBC, 1330 (5.0%) of them presented with distant metastasis. In the univariate analysis, all the variables indicated statistical significance. The significant variables were subsequently enlisted into the multivariate logistic regression analysis. Age > 50, higher clinical stage T and N, and tumor size > 5 cm were independent risk factors for distant metastasis of primary TNBC. Moreover, higher clinical stage T and stage N were independent risk factors for bone metastasis of the patients. TNBC patients with either bone or visceral metastasis have poor survival, with brain metastasis worst of all, though the OS difference was not statistically significant. Conclusions: TNBC patients with larger age, higher clinical stage, larger tumor size were more predisposed to have distant metastasis. Great attention should be paid to the prognosis of these patients with distant metastasis.

show abstract

Section: Discussionsupporting

confidence: 73%

Risk factors for distant metastasis of patients with primary triple-negative breast cancer

Yao

Chu

et al. 2019

Bioscience Reports

View full text Add to dashboard Cite

show abstract

“…A recent study had proposed the prognostic significance of the mLNR with TNBC patients. [10] To the best of our knowledge, our work is the largest study demonstrating the prognosis prediction of mLNR and grading in breast cancer patients with different molecular subtypes. Moreover, we found that the G-R staging system could identify the prognosis of breast cancer patients in Luminal and TNBC subtypes (Fig.…”

Section: Discussionmentioning

confidence: 99%

“…[5–7] Till now, no consensus has been reached on the robust and reproducible classification of metastatic lymph node ratio (mLNR), [8] and limited studies revealing the prognostic value of mLNR in breast cancer patients with different molecular subtypes have been reported. [9,10]…”

Section: Introductionmentioning

confidence: 99%

Grade-lymph node ratio predicts the survival of breast cancer in different molecular types

Liu

Zhuo

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…They are characterized by higher invasiveness, heterogeneity, and a relatively poorer outcome than other subtypes (2)(3)(4). The clinical outcome of TNBC is associated with age at diagnosis, race, tumor size, histological grade, lymph node status, and the BRCA1 mutation as reported in many studies (1,5,6). Unlike other subtypes of breast cancer that receive treatments, such as endocrine therapy or trastuzumab, the main and only current systemic treatment option for patients with TNBC is chemotherapy (2).…”

Section: Introductionmentioning

confidence: 99%

The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy

Chen

Wang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a subtype with distinct heterogeneity, high invasiveness, and poorer prognosis. There is a controversy about adjuvant chemotherapy (ACT) at the T1aN0M0 stage. This study was carried out to assess the survival benefit of ACT for these patients. Methods: We identified 1,099 patients with T1aN0M0 TNBC who were diagnosed between 2010 and 2016 from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariable analyses were conducted to determine factors related to survival. One-to-one (1:1) propensity score matching (PSM) was applied to construct a matched sample consisting of pairs of ACT and non-ACT subjects. Breast cancer-specific survival (BCSS) and overall survival (OS) of the two groups were evaluated by Kaplan-Meier plots and Cox proportional hazard regression models. Stratified analysis according to different variables was also performed. Results: No obvious differences in demographic or clinical characteristics were found between patients who had ACT and those without ACT therapy in terms of race, marital status, laterality, or radiation therapy. A higher proportion of patients who were older, had a higher histological grade tumor, and who received breast-conserving surgery had adjuvant chemotherapy. The ACT group did not exhibit better survival in BCSS or OS before PSM. After PSM, the ACT and non-ACT groups consisted of 255 patients, respectively, and Kaplan-Meier curves and multivariate analysis both indicate that adjuvant chemotherapy was not associated with better survival in terms of BCSS or OS. Furthermore, we did not observe any survival advantage in any subgroup irrespective of age, race, marital status, histological grade, surgery type, or radiotherapy status. Conclusions: The study results indicate that there is no strong association between ACT and better survival in T1aN0M0 TNBC. It implies that the chemotherapy decision should be made cautiously and further research into therapeutic strategies are needed in T1aN0M0 TNBC patients.

show abstract

The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer

Cited by 19 publications

References 27 publications

Risk factors for distant metastasis of patients with primary triple-negative breast cancer

Risk factors for distant metastasis of patients with primary triple-negative breast cancer

Grade-lymph node ratio predicts the survival of breast cancer in different molecular types

The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy

Contact Info

Product

Resources

About